Business, energy, technology, markets and global industry news from Business News Today

CEL-SCI Corporation

PharmaDeviceNews CEL-SCI Corporation
CEL-SCI’s 212-patient Multikine Phase 3 confirmatory study will test the investigational immunotherapy in biomarker-selected patients with newly diagnosed head and neck cancer. Representative image.
Pharma & Biotech

Multikine is back in Phase 3, but can CEL-SCI turn a striking subgroup signal into approval?

CEL-SCI launches a 212-patient Multikine Phase 3 study, but subgroup validation, funding and regulatory execution remain decisive.

Read More
Representative image of oncology specialists reviewing head and neck cancer scans in a Saudi clinical setting, reflecting CEL-SCI Corporation’s Multikine partnership with Amarox and its potential regulatory pathway for cancer immunotherapy in Saudi Arabia.
Pharma & Biotech

Can CEL-SCI’s Saudi Arabia deal turn Multikine into a real commercial oncology test?

Multikine still awaits a commercial breakthrough. CEL-SCI’s Saudi deal tests whether regional oncology access can change that trajectory.

Read More